NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $4.20 -0.01 (-0.24%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$4.22 +0.01 (+0.36%) As of 10/23/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arbutus Biopharma Stock (NASDAQ:ABUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$4.12▼$4.2250-Day Range$4.11▼$5.2152-Week Range$3.50▼$5.45Volume2.03 million shsAverage Volume7.00 million shsMarket Capitalization$832.06 millionP/E Ratio5.32Dividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing novel therapies for chronic hepatitis B virus (HBV) infection. Its research is aimed at addressing multiple stages of the HBV lifecycle, with the long-term goal of developing functional cures rather than therapies that only suppress the virus. The company’s pipeline has included investigational medicines such as AB-729, an RNA interference therapeutic designed to reduce hepatitis B surface antigen, and other antiviral candidates intended to inhibit viral replication. Arbutus has also developed expertise in lipid nanoparticle delivery technology, which is used to help deliver nucleic acid-based medicines into cells. Arbutus traces its corporate history to Tekmira Pharmaceuticals and adopted the Arbutus Biopharma name in 2015. The company is headquartered in Warminster, Pennsylvania, and its shares trade on the Nasdaq under the symbol ABUS. William R. Collier has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Arbutus Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreABUS MarketRank™: 2.59388412017 of 5 starsArbutus Biopharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 480th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingArbutus Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialArbutus Biopharma has a consensus price target of $5.00, representing about 19.0% upside from its current price of $4.20.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is 5.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is 5.32, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 10.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.46% of the float of Arbutus Biopharma has been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 3.53, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 84.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.68 News SentimentArbutus Biopharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest5 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABUS Stock News HeadlinesArbutus Biopharma's AB-101 Gets FDA Hold Lifted In Hepatitis B ProgramOctober 22 at 11:54 AM | rttnews.comArbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B DrugOctober 22 at 11:54 AM | finance.yahoo.comEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.October 25 at 1:00 AM | Behind the Markets (Ad)Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 InhibitorOctober 22 at 8:00 AM | globenewswire.comReviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)October 21, 2026 | americanbankingnews.comArbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV CureOctober 8, 2026 | seekingalpha.comArbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender OfferOctober 2, 2026 | marketscreener.comMTranche Update on Arbutus Biopharma Corporation's Equity Buyback Plan announced on August 21, 2026.October 1, 2026 | marketscreener.comMSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $4.81 on January 1st, 2026. Since then, ABUS shares have decreased by 12.7% and is now trading at $4.20. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corporation (NASDAQ:ABUS) released its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The biopharmaceutical company earned $1.01 million during the quarter, compared to analyst estimates of $0.70 million. Arbutus Biopharma had a net margin of 84.22% and a trailing twelve-month return on equity of 90.98%. Is Arbutus Biopharma buying back stock? Arbutus Biopharma's Board of Directors approved a stock buyback plan on Friday, August 21st 2026, which allows the company to repurchase $0 in shares, according to EventVestor. This allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board believes its stock is undervalued. Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's top institutional shareholders include Two Seas Capital LP (4.11%), Assenagon Asset Management S.A. (0.31%), SBI Securities Co. Ltd. (0.01%) and State of Alaska Department of Revenue (0.01%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Tesla (tsla), NIO (NIO), Sorrento Therapeutics (SRNE), Plug Power (PLUG), Moderna (MRNA), Inovio Pharmaceuticals (INO) and NVIDIA (NVDA). Company Calendar Last Earnings8/13/2026Today10/25/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 11 days, ABUS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABUS CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees19Year Founded2005Price Target and Rating Average Price Target for Arbutus Biopharma$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+19.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.79 Trailing P/E Ratio5.32 Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.50 million Net Margins84.22% Pretax Margin84.22% Return on Equity90.98% Return on Assets82.34% Debt Debt-to-Equity RatioN/A Current Ratio81.42 Quick Ratio81.42 Sales & Book Value Annual Sales$14.08 million Price / Sales59.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book10.50Miscellaneous Outstanding Shares198,110,000Free Float158,683,000Market Cap$832.06 million OptionableOptionable Beta0.76 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ABUS) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.